Journal Article
. 2014 Jan; 2(1):19-26.
doi: 10.1158/2326-6066.CIR-13-0152.

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer

Lee P Richman 1 Robert H Vonderheide 1 
  • PMID: 24416732
  •     26 References
  •     40 citations


Agonists of the TNF superfamily of receptors hold promise as novel therapy for cancer. Recent data on agonistic anti-murine TNF receptors (TNFR) such as CD40 suggest that the specific engagement of Fc-receptor (FcR) is required for optimal antitumor effects, prompting calls to engineer anti-human CD40 and other TNFR mAb accordingly. CP-870,893 is a fully human anti-CD40 mAb, selected in part because it is an IgG2 which is presumed to have poor reactivity with FcR; however, CP-870,893 has been evaluated in multiple clinical trials with beneficial activity in patients with melanoma, pancreatic and other cancers. Here, we confirmed that the activity of anti-murine CD40 mAb was dependent on FcγRIIB engagement, was decreased significantly in FcγRIIB (-/-) mice, and upon Fc-crosslinking anti-mouse CD40 mAb enhanced the activation of antigen presenting cells. In contrast, the CP-870,893-mediated activation of human B cells was not enhanced with anti-IgG-crosslinking nor abrogated when used as an F(ab)'2 reagent. Crosslinking of CP-870,893 using the CD32-expressing K562 cells yielded an Fc-dependent modest increase in the expression of some activation markers relative to that of the soluble CP-870,893 mAb. Classic Fc-dependent functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC) were minimal for CP-870,893 as compared to the IgG1 anti-CD20 mAb rituximab, which mediated both ADCC and CMC in parallel assays. Anti-mouse CD40 mAb competed for the CD40 ligand binding site, but CP-870,893 did not. Thus, Fc-crosslinking is not an essential requirement for agonistic anti-human CD40 mAb, whose potency is more dependent on the CD40 epitope recognized and the strength of the signal achieved.

Keywords: CD40; Fc Receptor; tumor immunity.

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
Help for cytotoxic-T-cell responses is mediated by CD40 signalling.
S R Bennett, F R Carbone, +3 authors, W R Heath.
Nature, 1998 Jun 12; 393(6684). PMID: 9624004
Highly Cited.
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Richard S Kornbluth, Mariusz Stempniak, Geoffrey W Stone.
Int Rev Immunol, 2012 Jul 19; 31(4). PMID: 22804572    Free PMC article.
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Ronald P Gladue, Timothy Paradis, +8 authors, Vahe Bedian.
Cancer Immunol Immunother, 2011 Apr 12; 60(7). PMID: 21479995
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
Ann L White, H T Claude Chan, +10 authors, Martin J Glennie.
J Immunol, 2011 Jul 12; 187(4). PMID: 21742972
Agonistic CD40 antibodies and cancer therapy.
Robert H Vonderheide, Martin J Glennie.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460534    Free PMC article.
Highly Cited.
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Fubin Li, Jeffrey V Ravetch.
Science, 2011 Aug 20; 333(6045). PMID: 21852502    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Fubin Li, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2012 Jun 23; 109(27). PMID: 22723355    Free PMC article.
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Erica L Carpenter, Rosemarie Mick, Jens Rüter, Robert H Vonderheide.
J Transl Med, 2009 Nov 13; 7. PMID: 19906293    Free PMC article.
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.
Pierre Bruhns, Bruno Iannascoli, +4 authors, Marc Daëron.
Blood, 2008 Nov 20; 113(16). PMID: 19018092
Highly Cited.
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Andrew J Rech, Rosemarie Mick, +13 authors, Robert H Vonderheide.
Sci Transl Med, 2012 May 18; 4(134). PMID: 22593175    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function.
J E Salmon, J C Edberg, N L Brogle, R P Kimberly.
J Clin Invest, 1992 Apr 01; 89(4). PMID: 1532589    Free PMC article.
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
Robert H Vonderheide, Jennifer M Burg, +5 authors, Omid Hamid.
Oncoimmunology, 2013 Mar 14; 2(1). PMID: 23483678    Free PMC article.
CD40-CD40 ligand.
C van Kooten, J Banchereau.
J Leukoc Biol, 2000 Jan 27; 67(1). PMID: 10647992
Highly Cited. Review.
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
Jens Rüter, Scott J Antonia, +2 authors, Robert H Vonderheide.
Cancer Biol Ther, 2010 Sep 22; 10(10). PMID: 20855968    Free PMC article.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.
J P Ridge, F Di Rosa, P Matzinger.
Nature, 1998 Jun 12; 393(6684). PMID: 9624003
Highly Cited.
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
P W Parren, P A Warmerdam, +6 authors, J G van de Winkel.
J Clin Invest, 1992 Oct 01; 90(4). PMID: 1401085    Free PMC article.
Highly Cited.
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Gregory L Beatty, Drew A Torigian, +8 authors, Peter J O'Dwyer.
Clin Cancer Res, 2013 Aug 29; 19(22). PMID: 23983255    Free PMC article.
Highly Cited.
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Robert H Vonderheide, Keith T Flaherty, +12 authors, Scott J Antonia.
J Clin Oncol, 2007 Mar 01; 25(7). PMID: 17327609
Highly Cited.
Prospect of targeting the CD40 pathway for cancer therapy.
Robert H Vonderheide.
Clin Cancer Res, 2007 Feb 24; 13(4). PMID: 17317815
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Nicholas S Wilson, Becky Yang, +17 authors, Avi Ashkenazi.
Cancer Cell, 2011 Jan 22; 19(1). PMID: 21251615
Highly Cited.
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
S P Schoenberger, R E Toes, +2 authors, C J Melief.
Nature, 1998 Jun 12; 393(6684). PMID: 9624005
Highly Cited.
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
Marcela V Maus, Anna K Thomas, +5 authors, Carl H June.
Nat Biotechnol, 2002 Feb 01; 20(2). PMID: 11821859
Highly Cited.
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.
Lee P Richman, Robert H Vonderheide.
Oncoimmunology, 2014 Aug 07; 3. PMID: 25097801    Free PMC article.
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Ann L White, H T Claude Chan, +15 authors, Martin J Glennie.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500122    Free PMC article.
Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.
Yong Zhang, Xiaoyan Hu, +7 authors, Li Liu.
J Exp Clin Cancer Res, 2015 Feb 06; 34. PMID: 25651850    Free PMC article.
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Kevin Van der Jeught, Lukasz Bialkowski, +7 authors, Karine Breckpot.
Oncotarget, 2015 Feb 16; 6(3). PMID: 25682197    Free PMC article.
Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.
Elizabeth A Thompson, Frank Liang, +7 authors, Karin Loré.
J Immunol, 2015 Jul 01; 195(3). PMID: 26123354    Free PMC article.
Influence of immunoglobulin isotype on therapeutic antibody function.
Stephen A Beers, Martin J Glennie, Ann L White.
Blood, 2016 Jan 15; 127(9). PMID: 26764357    Free PMC article.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Simon J Dovedi, Grazyna Lipowska-Bhalla, +5 authors, Jamie Honeychurch.
Cancer Immunol Res, 2016 Jun 01; 4(7). PMID: 27241845    Free PMC article.
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Rony Dahan, Bryan C Barnhart, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265505    Free PMC article.
Highly Cited.
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.
Anke Redeker, Ramon Arens.
Front Immunol, 2016 Sep 23; 7. PMID: 27656185    Free PMC article.
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Gregory L Beatty, Yan Li, Kristen B Long.
Expert Rev Anticancer Ther, 2016 Dec 09; 17(2). PMID: 27927088    Free PMC article.
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul J Carter, Greg A Lazar.
Nat Rev Drug Discov, 2017 Dec 02; 17(3). PMID: 29192287
Highly Cited. Review.
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.
Sabine Hoves, Chia-Huey Ooi, +15 authors, Carola H Ries.
J Exp Med, 2018 Feb 14; 215(3). PMID: 29436396    Free PMC article.
Highly Cited.
Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.
Taylor T Chrisikos, Yifan Zhou, +3 authors, Haiyan S Li.
Mol Immunol, 2018 Mar 20; 110. PMID: 29549977    Free PMC article.
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Xiaojie Yu, H T Claude Chan, +14 authors, Ann L White.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576376    Free PMC article.
The Immune Revolution: A Case for Priming, Not Checkpoint.
Robert H Vonderheide.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634944    Free PMC article.
Highly Cited. Review.
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos.
Nat Rev Drug Discov, 2018 Jun 16; 17(7). PMID: 29904196
Highly Cited. Review.
Bispecific antibodies in cancer immunotherapy.
Eva Dahlén, Niina Veitonmäki, Per Norlén.
Ther Adv Vaccines Immunother, 2018 Jul 13; 6(1). PMID: 29998217    Free PMC article.
Highly Cited. Review.
Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.
Sang-Hoon Sin, Anthony B Eason, +7 authors, Dirk P Dittmer.
J Virol, 2018 Jul 20; 92(19). PMID: 30021906    Free PMC article.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Abhishek S Kashyap, Martina Schmittnaegel, +18 authors, Alfred Zippelius.
Proc Natl Acad Sci U S A, 2020 Jan 01; 117(1). PMID: 31889004    Free PMC article.
A bispecific IgG format containing four independent antigen binding sites.
Anne Ljungars, Torbjörn Schiött, +6 authors, Mikael Mattsson.
Sci Rep, 2020 Feb 02; 10(1). PMID: 32005942    Free PMC article.
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Maria A Argiriadi, Lorenzo Benatuil, +14 authors, Bradford L McRae.
BMC Mol Cell Biol, 2019 Aug 07; 20(1). PMID: 31382872    Free PMC article.
Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.
Johan M S van der Schoot, Felix L Fennemann, +18 authors, Ferenc A Scheeren.
Sci Adv, 2019 Sep 07; 5(8). PMID: 31489367    Free PMC article.
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Xiaobo Liu, Yingjie Zhao, +8 authors, Fubin Li.
Nat Commun, 2019 Sep 29; 10(1). PMID: 31562320    Free PMC article.
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Maria Georganaki, Mohanraj Ramachandran, +15 authors, Anna Dimberg.
Oncoimmunology, 2020 Apr 02; 9(1). PMID: 32231867    Free PMC article.
Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages.
Akihiro Maeda, Elisabeth Digifico, +2 authors, Paola Allavena.
Eur J Immunol, 2019 Feb 20; 49(5). PMID: 30779113    Free PMC article.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Xiaojie Yu, H T Claude Chan, +13 authors, Mark S Cragg.
Cancer Cell, 2020 May 23; 37(6). PMID: 32442402    Free PMC article.
CD40 agonist-induced IL-12p40 potentiates hepatotoxicity.
Caroline Bonnans, Graham Thomas, +10 authors, Yan Qu.
J Immunother Cancer, 2020 Jun 01; 8(1). PMID: 32474414    Free PMC article.
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.
Da-Ke Li, Wen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934743    Free PMC article.
A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo.
Valeria Governa, Alvaro Brittoli, +7 authors, Emanuele Trella.
Oncoimmunology, 2019 May 10; 8(5). PMID: 31069131    Free PMC article.
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Erin L Filbert, Pia K Björck, +2 authors, Xiaodong Yang.
Cancer Immunol Immunother, 2021 Jan 05; 70(7). PMID: 33392713    Free PMC article.
Agonistic CD40 Antibodies in Cancer Treatment.
Dijana Djureinovic, Meina Wang, Harriet M Kluger.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33804039    Free PMC article.
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
Raquel Delgado, Karoline Kielbassa, +5 authors, Eric Eldering.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34205588    Free PMC article.
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies.
Timothy N J Bullock.
Cell Mol Immunol, 2021 Jul 21; 19(1). PMID: 34282297    Free PMC article.
Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Valentina Ceglia, Sandra Zurawski, +6 authors, Gerard Zurawski.
J Immunol, 2021 Sep 24; 207(8). PMID: 34551965    Free PMC article.
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies.
Khiyam Hussain, Mark S Cragg, Stephen A Beers.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638388    Free PMC article.
Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
Rui Mao, Fan Yang, Tongtong Zhang, Ji Li.
Front Immunol, 2022 Jan 11; 12. PMID: 35003069    Free PMC article.
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Yan Tie, Fan Tang, Yu-Quan Wei, Xia-Wei Wei.
J Hematol Oncol, 2022 May 19; 15(1). PMID: 35585567    Free PMC article.